Can you explain why the approval of Gocovri is what is 'resulting' in the Phase 2b PD-LID trial? Seems like big competition to me, but I haven't compared the outcomes to date. Or maybe the information gleaned from the Gocovri trial is informing the redesign? That sort of makes sense.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links